Lupus

      RT @lexmeara: Can we use urine testing ( and all the cells, proteins, complements, DNA, rna) to predict LN response? Ple

      alexa meara lexmeara

      5 years ago
      Can we use urine testing ( and all the cells, proteins, complements, DNA, rna) to predict LN response? Plenary II @SalemAlmaani @BradRovin @RheumNow #ACR20 @OSUWexMed
      RT @RayZuoMD: Great talk #ACR20 Integrating bulk and single-cell RNA-sequencing @Kahlenberglab identifies clinically act

      Yu (Ray) Zuo RayZuoMD

      5 years ago
      Great talk #ACR20 Integrating bulk and single-cell RNA-sequencing @Kahlenberglab identifies clinically actionable 5-gene signatures that can effectively differentiate DM from cutaneous lupus lesions. @RheumNow @UMIntMed Also out in @JCI_insight https://t.co/uYS6OJH0Hf https://t.co/KR0wwDb5BK
      RT @Janetbirdope: 50% use septra/bactrim in SLE if immunesuppressed. I don’t use it unless if frequent serious infecti

      Janet Pope Janetbirdope

      5 years ago
      50% use septra/bactrim in SLE if immunesuppressed. I don’t use it unless if frequent serious infections or bad lungs as I am not convinced about the risk of PCP/PJP v risk of septra with adverse rxns in SLE. I await an admin database to give me the data @RheumNow #ACR20 https://t.co/3s2S9fIUVe
      RT @doctorRBC: Dr. Aggarwal Abs#0955 showed efficacy of IVIG in tx of Dermatomyositis.
      How/when do you use IVIG for tx

      Robert B Chao, MD doctorRBC

      5 years ago
      Dr. Aggarwal Abs#0955 showed efficacy of IVIG in tx of Dermatomyositis. How/when do you use IVIG for tx of DM? @RheumNow #ACR20
      RT @doctorRBC: Efficacy of IVIG in Dermatomyositis Treatment
      1st Placebo controlled RCT
      1️⃣79% responder by total im

      Robert B Chao, MD doctorRBC

      5 years ago
      Efficacy of IVIG in Dermatomyositis Treatment 1st Placebo controlled RCT 1️⃣79% responder by total improvement score vs. 44% 2️⃣Efficacy sustained thru wk 40 3️⃣6% serious AE - thromboembolic event @RheumNow #ACR20 Abs#0955 #ACRbest https://t.co/715h1UkZ9X
      RT @RHEUMarampa: ProDERM study:10% IVIG is effective and safe in pts with DM. First large PBO-controlled, randomized ph

      sheila RHEUMarampa

      5 years ago
      ProDERM study:10% IVIG is effective and safe in pts with DM. First large PBO-controlled, randomized ph 3 trial. @RheumNow #ACR20 abs0995 #ACRbest https://t.co/aJyASaAMlJ
      RT @DrMiniDey: #HCQ assoc. w/ ↓platelet activity & ↑vascular health in #SLE:
      - 132 patients, 108 on HCQ
      - Ex-viv

      Mrinalini Dey DrMiniDey

      5 years ago
      #HCQ assoc. w/ ↓platelet activity & ↑vascular health in #SLE: - 132 patients, 108 on HCQ - Ex-vivo expts show ↓platelet aggregation & downregulation of platelet functional pathways - HCQ may improve vascular health in SLE Abs#0870 #ACR20 @RheumNow https://t.co/ST9n2HGyhM
      RT @DrMiniDey: Data from MUSE & TULIP trials of #anifrolumab in #SLE show increased risk of #herpeszoster when compa

      Mrinalini Dey DrMiniDey

      5 years ago
      Data from MUSE & TULIP trials of #anifrolumab in #SLE show increased risk of #herpeszoster when compared to placebo. Most HZ events mild-moderate, cutaneous and resolved without discontinuation of drug. #RheumTwitter #lupus Abs#0849 #ACR20 @RheumNow https://t.co/8a6OcZmOso
      HCQ and QTc Prolongation: Dr David Liew
      5 years ago

      Dr. David Liew reviews abstracts #0431 presented at the ACR 2020 annual meeting - and shares the results of the Twitter poll he conducted asking when prescribing HCQ, is an EKG routinely ordered either before or doing.  

      HCQ Not Associated with QTc Length in SLE and RA Patients: Dr. Janet Pope @Janetbirdope #ACR20

      https://t.co/zPIaFIi

      Dr. John Cush RheumNow

      5 years ago
      HCQ Not Associated with QTc Length in SLE and RA Patients: Dr. Janet Pope @Janetbirdope #ACR20 https://t.co/zPIaFIiqr5 https://t.co/Wk8YQpIpo7
      Healthcare Disparities: Dr. Eric Dein
      5 years ago

      Dr. Eric Dein discusses abstracts #0049 (accessing patient portals) and #0045  (assessing rashes in patients of color in lupus) presented Friday at the 2020 ACR annual meeting.

      RT @Janetbirdope: Congrats to Dr S Izuka a clinical Rheumatolgy fellow for making a press release. Looking forward to fu

      Janet Pope Janetbirdope

      5 years ago
      Congrats to Dr S Izuka a clinical Rheumatolgy fellow for making a press release. Looking forward to full presentation next week. We published SLE pts had more adverse drug reactions than RA so I try to avoid sulfa drugs in SLE JRheum 2003;30:480-4 #ACR2020 https://t.co/spr6FsS1xg
      Does Hydroxychloroquine Hurt the Heart? Dr. Jonathan Kay
      5 years ago

      Boston-based rheumatologist Dr. Jonathan Kay examines an ACR 2020 study (abstract #0431) looking at whether hydroxychloroquine use has injured patients' hearts.

      Racial Disparities - Stroke, Heart Attacks Risks Higher in SLE: Dr. Kathryn Dao
      5 years ago

      Dr. Kathryn Dao discusses abstract #0433 presented Friday at the 2020 ACR annual meeting.

      Among a 402 pt PSS cohort, 10% fmet 2019 EULAR/ACR SLE Criteria. SSc-SLE overlap pts more likely to be female, AfricanAm

      Dr. John Cush RheumNow

      5 years ago
      Among a 402 pt PSS cohort, 10% fmet 2019 EULAR/ACR SLE Criteria. SSc-SLE overlap pts more likely to be female, AfricanAmerican, limited cut.SSc, U1RNP and have similar rates of severe SSc-specific organ damage /mortality. #ACR20 Abstr#0401 https://t.co/CVcFyx9AxS https://t.co/3SAKZ9CZGS

      Catch up on Conference Podcasts

      ×